1-9 of 9
Jeremy A. Ross, PhD
Close
Sort by
Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 925.
https://doi.org/10.1182/blood-2019-124407
Published: 2019
Journal Articles

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

Deeksha Vishwamitra, Christine Mantis, PhD, Dipica Haribhai, PhD, Tamar Uziel, PhD, Joel D. Leverson, PhD, James M. Pauff, MD PhD, Orlando F. Bueno, MD PhD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1896.
https://doi.org/10.1182/blood-2019-128672
Published: 2019
Journal Articles

Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Francesca Gay, MD, Gábor Mikala, MD PhD, Elizabeth A Punnoose, PhD, Wan-Jen Hong, MD, Anjla Sood, MD, Muhammad Jalaluddin, PhD, Jeremy A. Ross, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1888.
https://doi.org/10.1182/blood-2019-126015
Published: 2019
Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip
Journal: Blood
Blood (2019) 134 (Supplement_1): 546.
https://doi.org/10.1182/blood-2019-128373
Published: 2019
Journal Articles

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Wendy Stock, MD, Elias Jabbour, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jeffrey Rubnitz, MD PhD, Jessica Leonard, MD, Charles G. Mullighan, MBBS, MD, Seong Lin Khaw, MD, Susan I. Vear, MD MSCI, Joseph T. Opferman, PhD, Ahmed Hamed Salem, PhD FCP, Michelle Schmidt, Bo Tong, PhD, Lang Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Bensman, Amanda Jacobson, PhD, Robin Norris, MD MS, MPH, Thomas Alexander, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 285.
https://doi.org/10.1182/blood-2019-126977
Published: 2019
Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Michele Cavo, Javier De La Rubia, Rakesh Popat, Cristina Gasparetto, MD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, Philippe Moreau, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Michael E O'Dwyer, MD, Mamta Garg, MD FRCP, FRCPath, Elizabeth A Punnoose, PhD, Muhammad Jalaluddin, PhD, Jia Jia, PhD MBA, Xiaoqing Yang, PhD, Yan Sun, PhD, James E. Ward, MD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 142.
https://doi.org/10.1182/blood-2019-126094
Published: 2019
Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 926.
https://doi.org/10.1182/blood-2019-125871
Published: 2019
Journal Articles

Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Luciano J Costa, MD PhD, Edward A. Stadtmauer, MD FACP, Gareth Morgan, MD, Gregory Monohan, MD, Tibor Kovacsovics, MD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L Kaufman, MD, Mehrdad Mobasher, MD MPH, Kevin J. Freise, PhD, Jeremy A. Ross, PhD, John Pesko, PhD, Wijith Munasinghe, PhD, Saketh Gudipati, MD, Sarah Mudd, PhD, Orlando Bueno, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 303.
https://doi.org/10.1182/blood-2018-99-117026
Published: 2018
Journal Articles

Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Thomas Alexander, MD MPH, Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Elias J. Jabbour, MD, Seong Lin Khaw, MD, Charles G. Mullighan, MBBS, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jessica Leonard, MD, Robin Norris, MD, Jeffrey Rubnitz, MD PhD, Susan I. Vear, MD MSCI, Michelle Schmidt, Bo Tong, PhD, Ying Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Rosenwinkel, Amanda Jacobson, PhD, Su Young Kim, MD PhD, Wendy Stock, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3966.
https://doi.org/10.1182/blood-2018-99-113464
Published: 2018